Abstract:The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the resulting ability to generate monoclonal antibodies (mAbs) initiated a new era in antibody research and clinical development. However, limitations of the hybridoma technology as a routine antibody generation method in conjunction with high immunogenicity responses have led to the development of alternative approaches for the streamlined identification of most effective antibodies. Within this context, display selection technologies such as phage display, ribosome display, yeast display, bacterial display, and mammalian cell surface display have been widely promoted over the past three decades as ideal alternatives to traditional hybridoma methods. The display of antibodies on phages is probably the most widespread and powerful of these methods and, since its invention in late 1980s, significant technological advancements in the design, construction, and selection of antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages. With evolving novel disease targets and the emerging of a new generation of therapeutic antibodies, such as bispecific antibodies, antibody drug conjugates (ADCs), and chimeric antigen receptor T (CAR - T) cell therapies, it is clear that phage display is expected to continue to play a central role in antibody development. Nevertheless, for non-standard and more demanding cases aiming to generate best-in-class therapeutic antibodies against challenging targets and unmet medical needs, in vivo phage display selections by which phage libraries are directly injected into animals or humans for isolating and identifying the phages bound to specific tissues offer an advantage over conventional in vitro phage display screening procedures. Thus, in the present review, we will first summarize a general overview of the antibody therapeutic market, the different types of antibody fragments, and novel engineered variants that have already been explored. Then, we will discuss the state-of-the-art of in vivo phage display methodologies as a promising emerging selection strategy for improvement antibody targeting and drug delivery properties.

Epivolve: A Protocol for Site-Directed Antibodies

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

Structure-Guided and Phage-Assisted Evolution of Therapeutic Antibodies to Reverse On-Target Point Mutation-Mediated Resistance

Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists

EPISOMAL VECTORS FOR STABLE PRODUCTION OF RECOMBINANT PROTEINS AND ENGINEERED ANTIBODIES

Structure and Sequence Engineering Approaches to Improve In Vivo Expression of Nucleic Acid-Delivered Antibodies

Improving antibodies by evolution and engineering

Revolutionizing Synthetic Antibody Design: Harnessing Artificial Intelligence and Deep Sequencing Big Data for Unprecedented Advances

Atomically accurate de novo design of single-domain antibodies

Identifying the Epitope Regions of Therapeutic Antibodies Based on Structure Descriptors

De Novo Evolution of an Antibody‐Mimicking Multivalent Aptamer via a DNA Framework

Engineering Antibody Fusion Proteins for Targeted Intracellular Therapeutic Delivery

Avidity in antibody effector functions and biotherapeutic drug design

In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties

Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation

Epitope-Directed Antibody Elicitation by Genetically Encoded Chemical Cross-Linking Reactivity in the Antigen

Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments

Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity

Fine-epitope Mapping of an Antibody That Binds the Ectodomain of Influenza Matrix Protein 2